A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to compare the efficacy and safety of OT-101 in
combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX
alone in patients with advanced and unresectable or metastatic pancreatic cancer.